Options
Jung, Klaus
Loading...
Preferred name
Jung, Klaus
Official Name
Jung, Klaus
Alternative Name
Jung, K.
Now showing 1 - 2 of 2
2009Journal Article [["dc.bibliographiccitation.firstpage","78"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","Journal of Proteomics & Bioinformatics"],["dc.bibliographiccitation.lastpage","87"],["dc.contributor.author","Jung, Klaus"],["dc.contributor.author","Poschmann, Gereon"],["dc.contributor.author","Podwojski, Katharina"],["dc.contributor.author","Eisenacher, Martin"],["dc.contributor.author","Kohl, Michael"],["dc.contributor.author","Pfeiffer, Kathy"],["dc.contributor.author","Meyer, Helmut E."],["dc.contributor.author","Stühler, Kai"],["dc.contributor.author","Stephan, Christian"],["dc.date.accessioned","2019-07-09T11:52:47Z"],["dc.date.available","2019-07-09T11:52:47Z"],["dc.date.issued","2009"],["dc.description.abstract","Differential proteome analyses focus on the detection and quantification of expression changes between samples from different biological groups. While the significance of an expression change is detected by some statistical test, the strength of an expression change is usually quantified by some ratio estimate, e.g. the ‘fold change’. Due to its quantitative character, the fold change is more intuitively for biologists than the decision of a statistical test. However, strong expression changes are often misleading if this change is not significant. For this reason, we propose the employment of confidence intervals, adjusted for multiple hypotheses testing, which naturally comprise both, test decision and quantification. The adjusted confidence intervals can be used for making test decisions under the control of error rates typically considered in multiple hypotheses testing (e.g. the familywise error rate or the false discovery rate). For biologists, test decisions based on adjusted confidence intervals offer a more intuitive method for selecting proteins with a significant expression change between two groups. The length of the intervals can be used for sample size planning of upcoming experiments. Our approach is primarily addressed to protein expression data recorded by two-dimensional Difference Gel Electrophoresis."],["dc.identifier.doi","10.4172/jpb.1000064"],["dc.identifier.fs","550223"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/5947"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/60276"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.relation.issn","0974-276X"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.subject.ddc","610"],["dc.title","Adjusted Confidence Intervals for the Expression Change of Proteins observed in 2-Dimensional Difference Gel Electrophoresis"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]Details DOI2018Journal Article [["dc.bibliographiccitation.firstpage","26"],["dc.bibliographiccitation.journal","Journal of Clinical & Translational Endocrinology"],["dc.bibliographiccitation.lastpage","38"],["dc.bibliographiccitation.volume","13"],["dc.contributor.author","Blaschke, Martina"],["dc.contributor.author","Koepp, Regine"],["dc.contributor.author","Lenz, Christof"],["dc.contributor.author","Kruppa, Jochen"],["dc.contributor.author","Jung, Klaus"],["dc.contributor.author","Siggelkow, Heide"],["dc.date.accessioned","2019-07-09T11:45:44Z"],["dc.date.available","2019-07-09T11:45:44Z"],["dc.date.issued","2018"],["dc.description.abstract","Background: Crohn's disease (CD) is associated with a higher prevalence of osteoporosis, a complication that is recognized as a significant cause of morbidity. Its pathogenesis is controversial, but the activity of CD is one contributing factor. Methods: We stimulated SCP-1 cells (mesenchymal stem cell line) under osteogenic conditions with serum from adult patients with CD in the symptomatic phase (SP) and in remission (R) and with control sera. Concentrations of IL-6, IL-1 beta, and TNF alpha in the sera were measured. Patients were classified as normal or osteopenic/osteoporotic based on bone mineral density (BMD) T-score measurements. After 14 days in culture, protein expression and gene ontology (GO) annotation analysis was performed. Results: Cytokine concentrations (IL-6, IL-1 beta, TNF alpha) varied within sera groups. None of the cytokines were significantly increased in the symptomatic phase compared to remission. Protein analysis revealed 17 proteins regulated by the SP versus R phase sera of disease. A linear relationship between CDAI (Crohn's disease activity index) and normalized protein expression of APOA1 and 2, TTR, CDKAL1 and TUBB6 could be determined. Eleven proteins were found to be differentially regulated comparing osteoporosis-positive and osteoporosis-negative sera. Gene annotation and further analysis identified these genes as part of heme and erythrocyte metabolism, as well as involved in hypoxia and in endocytosis. A significant linear relationship between bone mineral density and normalized protein expression could be determined for proteins FABP3 and TTR. Conclusion: Our explorative results confirm our hypothesis that factors in serum from patients with CD change the protein expression pattern of human immortalized osteoblast like cells. We suggest, that these short time changes indeed influence factors of bone metabolism."],["dc.identifier.doi","10.1016/j.jcte.2018.06.002"],["dc.identifier.pmid","30003044"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/15299"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/59299"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.relation.issn","2214-6237"],["dc.rights","CC BY-ND 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by-nd/4.0"],["dc.subject.ddc","610"],["dc.title","Crohn's disease patient serum changes protein expression in a human mesenchymal stem cell model in a linear relationship to patients' disease stage and to bone mineral density"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]Details DOI PMID PMC